Thermo Fisher Scientific Inc. $TMO Shares Acquired by Swiss Life Asset Management Ltd

Swiss Life Asset Management Ltd raised its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.8% in the fourth quarter, Holdings Channel.com reports. The fund owned 46,801 shares of the medical research company’s stock after acquiring an additional 1,721 shares during the quarter. Swiss Life Asset Management Ltd’s holdings in Thermo Fisher Scientific were worth $27,119,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Vanguard Group Inc. grew its holdings in Thermo Fisher Scientific by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 34,133,702 shares of the medical research company’s stock valued at $19,778,774,000 after buying an additional 288,296 shares in the last quarter. Capital World Investors grew its holdings in Thermo Fisher Scientific by 7.4% in the 3rd quarter. Capital World Investors now owns 10,285,145 shares of the medical research company’s stock valued at $4,988,132,000 after buying an additional 706,572 shares in the last quarter. Franklin Resources Inc. grew its holdings in Thermo Fisher Scientific by 21.0% in the 3rd quarter. Franklin Resources Inc. now owns 5,925,671 shares of the medical research company’s stock valued at $2,874,069,000 after buying an additional 1,028,125 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in Thermo Fisher Scientific by 54.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 3,571,857 shares of the medical research company’s stock valued at $1,732,422,000 after buying an additional 1,262,967 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA grew its holdings in Thermo Fisher Scientific by 5.1% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 3,087,666 shares of the medical research company’s stock valued at $1,789,148,000 after buying an additional 150,668 shares in the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have issued reports on TMO shares. Weiss Ratings restated a “hold (c)” rating on shares of Thermo Fisher Scientific in a report on Wednesday, April 8th. DZ Bank assumed coverage on Thermo Fisher Scientific in a research report on Friday, March 27th. They issued a “buy” rating and a $610.00 price objective for the company. Morgan Stanley reiterated an “overweight” rating and issued a $620.00 price objective on shares of Thermo Fisher Scientific in a research report on Monday, April 27th. Jefferies Financial Group upgraded Thermo Fisher Scientific to a “strong-buy” rating in a research report on Friday, April 24th. Finally, Robert W. Baird lowered their price objective on Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating for the company in a research report on Friday, April 24th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, Thermo Fisher Scientific has a consensus rating of “Buy” and an average price target of $619.65.

Thermo Fisher Scientific Trading Down 2.8%

TMO opened at $452.14 on Tuesday. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $643.99. The business has a fifty day simple moving average of $491.19 and a 200-day simple moving average of $545.39. The firm has a market cap of $168.02 billion, a P/E ratio of 24.86, a P/E/G ratio of 2.06 and a beta of 0.88. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, topping the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The business had revenue of $11.01 billion during the quarter, compared to analyst estimates of $10.86 billion. During the same period last year, the business posted $5.15 earnings per share. The company’s quarterly revenue was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, equities analysts expect that Thermo Fisher Scientific Inc. will post 24.86 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, April 15th. Stockholders of record on Friday, March 13th were paid a $0.47 dividend. The ex-dividend date was Friday, March 13th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. This represents a $1.88 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific’s payout ratio is 10.34%.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 5,000 shares of the stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total value of $2,562,000.00. Following the sale, the chief executive officer directly owned 123,925 shares in the company, valued at approximately $63,499,170. This trade represents a 3.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Gianluca Pettiti sold 400 shares of the stock in a transaction on Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the sale, the chief operating officer owned 25,051 shares in the company, valued at approximately $11,590,095.66. The trade was a 1.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.